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Background: Despite safety concerns, unlicensed and off-label use of drugs in neonates has been reported in the literature. 





Impact of findings on practice:
	In clinical practice, drugs are more likely to be prescribed in an off-label manner rather than in an unlicensed manner among hospitalized neonates. 
	Benefits and risks associated with off-label and unlicensed use of drugs in neonates should be carefully considered.
	More research is needed to ascertain the safety and efficacy of off-label and unlicensed drug use.































Safe prescribing is particularly challenging in neonatal patients because most of the therapeutic agents have not been studied in this patient population and their benefit versus risk ratio is often supported only by limited evidence [1]. Unlicensed (UL) use refers to ‘using drugs that are not specifically licensed for use in pediatric population’ and off-label use refers to ‘using a drug outside the terms of their product license’; i.e., different indication, age range, dose or route of administration [2]. 
Unlicensed or off-label use of drugs is often associated with certain safety problems. Off-label and unlicensed use of drugs is more likely to lead to medication errors causing moderate harm in children [3]. Furthermore, it has been estimated that off-label or unlicensed use of medicines accounts for between 23% and 60% of all ADRs in children [4]. However, off-label and/or unlicensed use may not necessarily be always incorrect, but instead necessitated by certain medical conditions.
Saudi Food & Drug Authority (SFDA) is the governmental agency that regulates drug licensing in the Kingdom. Pharmaceutical companies are only allowed to promote licensed medicines for approved medical conditions [1]. Prescribers, however, are free to prescribe the most appropriate medicine for their patients. To the best of our knowledge, no study has examined the pharmacoepidemiology of unlicensed and off-label drug use among hospitalized neonates in Saudi Arabia. The current study was designed to fill this research gap by investigating the extent of off-label and unlicensed prescribing in neonates admitted in neonatology department of a tertiary-care hospital in Saudi Arabia. An additional objective was to identify patient-related risk factors associated with off-label prescribing. 
Ethics approval
The institutional Clinical Research Ethics Committee granted ethics approval (Ref number: KFUH-DON-04/08/2015) and waived the requirement for obtaining informed consent for reviewing patients’ medical records.
Method
Study settings
The present study was conducted at the neonatology department of a tertiary care teaching hospital in the Eastern Province. The neonatology department consists of two well-newborn nurseries (each contains 25 beds/cribs), one special care nursery (contains 20 cribs/beds), and one neonatal intensive care unit (NICU) (contains 10 beds/cribs). Newborns are admitted to one of these nurseries/wards based on their clinical condition. Neonates were prospectively recruited from well-newborn nurseries, special care nursery and NICU between January and March 2016. The pharmacy department uses a closed drug formulary developed in collaboration with the Pharmacy and Therapeutics Committee of the hospital.
 Study population
All consecutive admissions to all neonatal care levels during the study duration were screened were eligibility. Neonatal patients admitted to any neonatal unit/nursery for a minimum of 24 hours and prescribed with at least one drug were included in the study. Following drugs were also excluded: nutritional preparations, standard intravenous crystalloid solutions, oxygen and heparin used to maintain patency of intravenous lines.
Data collection
A structured data collection sheet was developed and pilot-tested to ensure uniformity in data collection. The recorded clinical variables included: birth weight, gestational age, gender, birth route, postnatal age, mechanical ventilation status, number and type and of medications administered. Data were extracted from electronic medical records by a clinical pharmacist. The following data were recorded for each drug prescription order: drug prescribed, drug formulation, route of administration, dose, frequency, and indication for a prescription. The treating physicians, resident doctors, and staff nurses were not aware of about the nature and scope of this study.

The prescribed drugs were uniformly coded using WHO Anatomic Therapeutic Classification (ATC) [2]. All recorded medications were reviewed for FDA approval for use in neonates by using the product monograph for each drug as a reference. These prescriptions were classified into three groups, according to the criteria published by Turner [3]: approved prescriptions according to label, off-label prescriptions, and unlicensed prescriptions. We defined off-label use as drugs given for an approved indication, but in an unapproved manner, including those given at a higher dose, greater frequency, to an age group, or by a route not described in the product monograph or a licensed drug given for indications for which its use has not been approved. An unlicensed drug was defined as a drug without a product license to use in neonates [2].

 Statistical analysis
Data were analyzed using IBM SPSS version 21.0. software.  Results for continuous variables are expressed as means and percentages. Univariate and multivariate logistic regression analyses were performed to identify factors associated with off-label use of medicines in neonates. Variables from univariate analysis with a P value of less than 0.20 were inserted into a multivariate logistic regression model to identify independent predictors of off-label use of drugs in neonates. Odds ratio (OR) with 95% confidence interval (95% CI) were computed along with corresponding P-value (P < 0.05).
Results
Clinical characteristics of patients
Table 1 shows demographic and clinical characteristics of the patients.  During the 3-month study period, 138 patients including 72 males (52%) and 66 females (48%) were enrolled in the study. The mean (±SD) postnatal age was 12  (8) days. The overall mean (±SD) length of hospital stay was 7.8 (6) days. The median gestational age (IQR) of the patients was 37 (35–39) weeks with 16 (12%) neonates were born preterm. About 81% (n=112)  of neonates were born with normal birth weight. 
Prevalence of off-label/unlicensed medications use
In total 583 prescriptions were made (mean 3.5 ± 2.3 per patient), involving 63 different drug products. The most common route of administration of drugs was intravenous (81%) followed by oral (9%), intramuscular (4.5 %), topical (2%), and via an endotracheal tube (1%).
 Of 583 prescriptions reviewed, 42.6% (n = 248) prescriptions had at least one drug for either an off-label (n = 173; 29.7%) or off-licensed  (n =75; 12.9%) use . Thirty-four percent (n=47) of patients received at least one off-label/unlicensed medicine. The number of off-label and unlicensed prescriptions per patient ranged from 0 to 5 (mean 2.24 ± 1.7) and from 0 to 2 (mean 0.29 ± 0.6), respectively. Administration of drug outside licensed age range(37%) was the most common category of off-label prescription followed by greater dose (25%), administration for indication outside licence (16.5%), frequency (more frequent) (11%), formulation outside license (6.5 %), and alternative routes of administration outside license (4%) . Piperacillin/tazobactam was the most frequently prescribed the off-label drug in ‘outside licensed age range’ category. The therapeutic class of off-label used drugs according to the  WHO Anatomical Therapeutic Chemical (ATC) classification included: antiinfectives (34%), alimentary tract and metabolism  (23%), nervous system (19%) and cardiovascular system (14%). The most frequently prescribed drugs used in an unlicensed manner were polystyrene sulfonate and mannitol
Risk factors associated with Off-label drug use in neonates




To best of our knowledge, this is the first study to assess the off-label and unlicensed use of medicines among neonates in the Kingdom of Saudi Arabia. In the present study, 42.5% of all prescriptions contained at least one off-label or unlicensed drug. In literature, the use of unlicensed and off-label medications in neonates ranges between 35 to 75% [4]. The wide differences in the literature can be attributed to variations in the definitions of off-label and unlicensed drugs used and heterogeneity in the studied patient population. The relatively less use of off-label and unlicensed drug in this study compared to previous studies [4] is probably because we recruited patients from three levels of care (Level 1: well-newborn nursery; Level II: special care nursery, and Level III NICU),  with a high percentage of patients from well-newborn nursery. Furthermore, some of the previous studies [4] had included blood products, intravenous fluids, and nutritional supplements, unlike the present study. 
Our results showed that newborn infants in NICU and mechanically ventilated newborns were 1.8 and 1.9 times more likely to be prescribed drugs for off-label use, respectively. These results are consistent with data from other countries [5, 6]. Studies conducted exclusively in NICUs showed that preterm and neonates with low birth weight are most vulnerable to receive more drugs than the mature ones [5]. However, birth weight was not found to be an independent predictor associated with off-label use in neonates in this study. 

We identified that systemic antibacterials were the most frequently used off-label drugs, followed by drugs that act on gastrointestinal and central nervous systems. Previous studies also reported a greater off-label utilization of antibiotics [4]. Among antibacterials group, piperacillin/tazobactam was the most frequently prescribed drug for off-label use. Among gastrointestinal drugs, ranitidine was the most frequently prescribed off-label drug despite safety concerns. A recent study has shown ranitidine use in newborns in NICU was associated with an increased risk of infections and mortality [7].
In our study, 12.9% of the prescriptions had at least one drug prescribed in an off-licensed manner. The proportion of unlicensed drug use in hospitalized neonates has been estimated between 0.2% and 36% [4].The most frequently prescribed drugs used in an unlicensed manner were polystyrene sulfonate and mannitol. 
Limitations:




Use of drugs in an off-label and/or unlicensed manner in hospitalised neonates was a common practice. The proportion of drugs used in an off-label manner was more common than in an unlicensed manner. Healthcare professionals should carefully assess benefits and risks associated with the off-label and unlicensed use of drugs in neonates. 
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Table 1: Demographic and clinical characteristics of the patient
Variable	Total N = 138N (%)
Gender	
  Male	72 (52)
  Female	66 (48)
Birth weight	
  Extremely low birth weight (≤ 1000g)	-
  Very low birth weight (≤ 1500g)	2 ((1)
  Low birth weight (≤2500g)	24 (17)
  Normal birth weight (2500-4000g)	112 (81)
  Macrosomia (≥4000g)	-
Gestational age	
  Pre-term (<37 weeks)	16 (12)
  Full term (37-40 weeks)	113 (82)
  Post-term (>42 weeks)	9 (7)
Type of delivery 	
  Vaginal	80 (58)
  Cesarean 	58 (42)
Levels of Neonatal Care	
  Level I: Well newborn nursery	73 (53)
  Level II: Special care nursery	44 (32)
  Level III: Neonatal intensive care unit (NICU)	21 (15)





















Page 16 of 16



